|

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

RECRUITINGSponsored by Asmaa Hassan mohamed Abdel Mawjoud
Actively Recruiting
SponsorAsmaa Hassan mohamed Abdel Mawjoud
Started2027-03-20
Est. completion2027-06-30
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04546945

Summary

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with hematologic malignancies.
* Newly diagnosed

Exclusion Criteria:

* Patients with hematologic disorders other than hematologic malignancies.

Conditions2

CancerHematologic Malignancies

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.